Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

William David

Neurology Boston, MA Medical Doctor

NPI 1750333605 CMS profile 698278

165 Cambridge St, Mgh Emg/Neuromuscular Unit 8Th Floor, Boston, MA 02114

Open in the dashboard

General payments

$45,205

39 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William David of Boston, MA is reported in the CMS Open Payments database as having received $45,205 across 39 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,100 15
2024 General $90 1
2023 General $5,295 11
2022 General $7,770 10
2021 General $26,200 1
2020 General $2,750 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William David
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to William David were reported at $3,100. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year William David Neurology median Middle half National median
2019 $0 $474 $118–$2,177 $163
2020 $2,750 $367 $82–$2,309 $114
2021 $26,200 $438 $104–$2,547 $132
2022 $7,770 $442 $103–$2,388 $149
2023 $5,295 $464 $119–$2,312 $160
2024 $90 $468 $119–$2,323 $164
2025 $3,100 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Pfizer Inc. $39,450 22 payments
  2. Natus Medical Incorporated $4,689 1 payment
  3. UCB, Inc. $1,050 15 payments
  4. Seqirus USA Inc $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Consulting Fee $39,450 22 payments
  2. Honoraria $4,689 1 payment
  3. Food and Beverage $1,067 16 payments
Products named General payments · program years 2020–2025
  1. Briviact $108 5 payments
  2. FLUCELVAX QUADRIVALENT $16 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

11

Median for Neurology: 833

Drug cost

$149,102

Median for Neurology: $202,670

Branded share of claims

100%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Radicava Ors Edaravone Brand 11 $149,102

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$129,257

Of which drugs: $72,006

Medicare patients

218

Average age 72

Services billed

14,222

112 women, 106 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 67%
Depression 34%
Ischemic heart disease 30%
Osteoporosis 24%
Diabetes 23%
Atrial fibrillation 19%
Chronic kidney disease 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 22 12,907 $64,344

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

39 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record